About Hemotune
Hemotune is a company based in Zurich (Switzerland) founded in 2017 by Lukas Langenegger and Carlos Andrea Mora. Hemotune has raised $28.86 million across 7 funding rounds from investors including Zurcher Kantonalbank, EIT Health and Hemex Health. Hemotune offers products and services including Blood Purification Platform and HemoSystem. Hemotune operates in a competitive market with competitors including Outset Medical, Fresenius, Medcura, ExThera Medical and Diality, among others.
- Headquarter Zurich, Switzerland
- Founders Lukas Langenegger, Carlos Andrea Mora
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hemotune Ag
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$28.86 M (USD)
in 7 rounds
-
Latest Funding Round
$15.6 M (USD), Series B
Mar 25, 2024
-
Investors
Zurcher Kantonalbank
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hemotune
Hemotune offers a comprehensive portfolio of products and services, including Blood Purification Platform and HemoSystem.
Platform using magnetic beads for purifying blood in septic shock cases.
System for multi-target blood purification to enhance patient outcomes.
People of Hemotune
Unlock access to complete
Funding Insights of Hemotune
Hemotune has successfully raised a total of $28.86M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $15.6 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Hemotune
Hemotune has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Zurcher Kantonalbank, EIT Health and Hemex Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A Zurich-based VC firm focused on early-stage life science companies.
|
Locked | Locked | Locked | |
|
Regulatory affairs and marketing services are provided for healthcare entities.
|
Locked | Locked | Locked | |
|
Venture capital investments are provided to deep-tech startups.
|
Locked | Locked | Locked |
Investor details for Hemotune
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hemotune
Investment portfolio details for Hemotune
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Hemotune
Detailed financials for Hemotune
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hemotune Comparisons
Peer comparison for Hemotune
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hemotune
Hemotune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Outset Medical, Fresenius, Medcura, ExThera Medical and Diality, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Hemodialysis machines with touchscreen displays are provided for medical use.
|
|
| Locked | Locked | Locked |
System-critical products and services for healthcare therapies are provided.
|
|
| Locked | Locked | Locked |
Developer of the device for controlling bleeding
|
|
| Locked | Locked | Locked |
Medical devices for the rapid treatment of bloodstream infections and pathogen-reduction in blood banking
|
|
| Locked | Locked | Locked |
Developer of portable hemodialysis device
|
Detailed competitors of Hemotune
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hemotune
Complete news archive for Hemotune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hemotune
Hemotune was founded in 2017.
Hemotune is headquartered in Zurich, Switzerland.
Lukas Langenegger is the current CEO of Hemotune. They have also founded this company.
Hemotune is a funded company, having raised a total of $28.86M across 7 funding rounds to date.
Hemotune was founded in 2017 in Zurich, Switzerland, within the medtech sector. A platform for blood purification is being developed, utilizing magnetic beads to restore immune balance in patients with septic shock. Operations focus on improving outcomes through this technology, with development centered in Switzerland. Key personnel include co-founders Lukas Langenegger as CEO and Carlos Andrea Mora.
Hemotune's top competitors include Outset Medical, Fresenius and Diality.
Hemotune offers Blood Purification Platform and HemoSystem.
Hemotune has 11 investors. Key investors include Zurcher Kantonalbank, EIT Health, Hemex Health, European Union, and Green Cross Medical Systems.